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Abstract
Background: Magnetic resonance spectroscopy (MRS) studies have identified elevated levels of the phospholipid
precursor phosphocholine (PC) and phosphoethanolamine (PE) as metabolic hallmarks of cancer. Unusually, however, PC
and PE levels are reduced in mutant isocitrate dehydrogenase 1 (IDHmut) gliomas that produce the oncometabolite 2-
hydroxyglutarate (2-HG) relative to wild-type IDH1 (IDHwt) gliomas. The goal of this study was to determine
the molecular mechanism underlying this unusual metabolic reprogramming in IDHmut gliomas.
Methods: Steady-state PC and PE were quantified using 31P-MRS. To quantify de novo PC and PE synthesis, we used
13C-MRS and measured flux to 13C-PC and 13C-PE in cells incubated with [1,2-13C]-choline and [1,2-13C]-ethanolamine.
The activities of choline kinase (CK) and ethanolamine kinase (EK), the enzymes responsible for PC and PE synthesis,
were quantified using 31P-MR-based assays. To interrogate the role of 2-HG, we examined IDHwt cells incubated with
2-HG and, conversely, IDHmut cells treated with the IDHmut inhibitor AGI-5198. To examine the role of hypoxia-
inducible factor 1-α (HIF-1α), we silenced HIF-1α using RNA interference. To confirm our findings in vivo and in the
clinic, we studied IDHwt and IDHmut orthotopic tumor xenografts and glioma patient biopsies.
Results: De novo synthesis of PC and PE was reduced in IDHmut cells relative to IDHwt. Concomitantly, CK activity and EK
activity were reduced in IDHmut cells. Pharmacological manipulation of 2-HG levels established that 2-HG was responsible
for reduced CK activity, EK activity, PC and PE. 2-HG has previously been reported to stabilize levels of HIF-1α, a known
regulator of CK activity. Silencing HIF-1α in IDHmut cells restored CK activity, EK activity, PC and PE to IDHwt levels. Our
findings were recapitulated in IDHmut orthotopic tumor xenografts and, most importantly, in IDHmut patient biopsies,
validating our findings in vivo and in the clinic.
Conclusions: This study identifies, to our knowledge for the first time, a direct role for 2-HG in the downregulation of CK
and EK activity, and thereby, PC and PE synthesis in IDHmut gliomas. These results highlight the unusual reprogramming
of phospholipid metabolism in IDHmut gliomas and have implications for the identification of MRS-detectable metabolic
biomarkers associated with 2-HG status.
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Background
Mutations in isocitrate dehydrogenase 1 (IDH1) are char-
acteristic of low-grade gliomas and secondary upgraded
glioblastomas [1]. The wild-type IDH1 (IDHwt) enzyme
converts isocitrate to α-ketoglutarate (α-KG), while the
mutant IDH1 (IDHmut) enzyme converts α-KG to the
oncometabolite 2-hydroxyglutarate (2-HG). By competi-
tively inhibiting the activity of α-KG-dependent dioxy-
genases such as prolyl hydroxylases, JmJc-domain histone
demethylases, and the TET family of 5-methylcytosine
hydroxylases, 2-HG induces alterations in epigenetics and
cell signaling that ultimately drive tumorigenesis [1, 2].
The IDH1 mutation also induces metabolic reprogram-
ming that often differs from that observed in IDHwt
gliomas [3]. For instance, the Warburg effect, character-
ized by increased glucose uptake and lactate production,
is a metabolic feature of cancer cells, including IDHwt
gliomas [4]. However, IDHmut gliomas downregulate
lactate production compared to IDHwt [5, 6]. Likewise, el-
evated phospholipid metabolism is a hallmark of cancer.
Phosphocholine (PC) and phosphoethanolamine (PE) are
intermediates in the synthesis of phosphatidylcholine
(PtdCho) and phosphatidylethanolamine (PtdE), which are
quantitatively the most important phospholipids in the
cell [7]. Levels of PC, and oftentimes PE, are elevated in
every cancer studied to date, including IDHwt gliomas
[8, 9]. This effect is typically mediated by overexpression
and increased activity of choline kinase (CK) and, less
frequently, ethanolamine kinase (EK), the enzymes that
phosphorylate choline and ethanolamine to PC and PE,
respectively (Fig. 1a) [8–10]. Unusually, however, we and
others have previously found that steady-state PC levels
are reduced in IDHmut cells relative to IDHwt [11, 12],
while Esmaeili et al. showed reduced levels of PE in IDH-
mut gliomas relative to IDHwt [13].
Magnetic resonance spectroscopy (MRS) is a non-
invasive metabolic imaging modality that can be used to
quantify metabolism in cells, animals, and patients [14].
1H- and 31P-MRS quantify steady-state metabolite levels,
whereas 13C-MRS monitors metabolic fluxes [15]. 31P-
MRS can detect PC and PE as well as the phospholipid
breakdown products glycerophosphocholine (GPC) and
glycerophosphoethanolamine (GPE). 1H-MRS detects
total choline (tCho)-containing metabolites comprised of
choline, PC, and GPC. Elevated levels of PC and tCho
can be detected using MRS in most tumors compared to
normal tissue, including high-grade IDHwt glioblast-
omas, and have emerged as non-invasive imaging bio-
markers of cancer [16–18]. The reduction in PC and PE
observed in IDHmut gliomas was therefore considered
as unusual and with potential for serving as an indicator
of IDH status [3, 11–13].
The goal of this study was to investigate the molecular
mechanism driving the modulation of PC and PE levels
in IDHmut gliomas in order to potentially validate these
compounds as metabolic imaging biomarkers of the IDH
mutation [11–13]. Using genetically engineered and
patient-derived cell models as well as orthotopic tumor
xenografts, we show that 2-HG production in IDHmut
gliomas leads to reduced CK and EK activity and thereby
reduced PC and PE synthesis and steady-state levels.
Our data indicates that this effect is mediated by hypoxia
inducible factor-1α (HIF-1α). Importantly, we confirmed
our findings in glioma patient biopsies, highlighting their
clinical relevance. Collectively, our study illuminates the
mechanism underlying the unusual downregulation of
choline and ethanolamine metabolism in IDHmut gli-
omas and also points to the potential and challenges as-
sociated with PC and PE as biomarkers of these tumors.
Methods
Cell culture
The generation and characterization of U87 and NHA cells
expressing IDHwt (U87IDHwt and NHAIDHwt) or IDH1
R132H mutant enzyme (U87IDHmut and NHAIDHmut)
have been previously described [11]. Briefly, all cell lines
were maintained between passages 15 and 30 in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
fetal calf serum, 2 mM glutamine, and 100 U/ml penicillin
and streptomycin under normoxic conditions. In addition,
the medium was supplemented with 28 μM choline (the
normal concentration of choline in DMEM is 28 μM and,
therefore, the final concentration of choline was 56 μM)
and 56 μM ethanolamine in order to mimic the conditions
used in our 13C-MRS studies (see below). We established
that the addition of choline and ethanolamine as described
above did not alter the growth as determined by cell count-
ing or proliferation as measured in doubling time of our
cells for at least 15 passages. Nor did the addition of choline
and ethanolamine alter total PC and PE levels as deter-
mined by examination of 31P-MRS data from cell extracts
as well as bioreactors. The BT54 patient-derived model was
provided by H.A.L and J.G.C and cultured as neurospheres
in serum-free medium as previously described [19] and the
Neurocult medium supplemented with a concentration of
56 μM choline and 56 μM ethanolamine. All cell lines were
routinely tested for mycoplasma contamination and au-
thenticated by short tandem repeat fingerprinting (Cell Line
Genetics) and assayed within 6 months of authentication.
Cell treatments
IDHwt and IDHmut siHIF-1α cells were treated with
1 mM D-2-HG (Sigma-Aldrich) for 24 h. U87IDHwt
and U87IDHmut siHIF-1α cells were permeabilized with
0.01% digitonin (Sigma-Aldrich) in phosphate-buffered
saline (PBS) for 10 min prior to treatment. IDHmut cells
were treated with 10 μM AGI-5198 for 72 h. DMSO was
used as vehicle control in all cases.
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RNA interference
SMARTpool siRNA (Dharmacon, GE) against human
HIF-1α (M-004018-05) and non-targeting siRNA pool
#2 (D-001206-14-05) were transfected according to
manufacturer’s instructions. Briefly, 2 × 106 U87 or
NHA cells, or 2.5 × 106 BT54 cells as neurospheres,
were seeded in a 150-mm dish. Twenty-four hours
later, cells were transfected with 25 nM siRNA using
DharmaFECT 4 transfection reagent (GE) and were
incubated at 37 °C for an additional 72 h prior to
harvesting for further studies.
MRS of cell extracts
Metabolite extraction was performed using the dual-
phase methanol-chloroform extraction method [11], and
spectra were recorded on a 500-MHz spectrometer
(Bruker) equipped with a Triple Resonance CryoProbe.
1H-MR spectra (1D water presaturation ZGPR sequence,
90° flip angle, 3 s relaxation delay, 256 acquisitions),
proton-decoupled 13C-MR spectra (30° flip angle, 3 s re-
laxation delay, 2048 acquisitions) and proton-decoupled
31P-MR spectra (30° flip angle, 2.6 s relaxation delay,






Fig. 1 PC and PE synthesis is downregulated in IDHmut glioma cells. a Metabolic pathways of choline and ethanolamine phospholipid
metabolism in mammalian cells. CK, choline kinase; EK, ethanolamine kinase; CCT, CTP:PC cytidylyltransferase; ECT, CTP:PE cytidylyltransferase;
CHPT, choline phosphotransferase; EHPT, ethanolamine phosphotransferase; PLA2, phospholipase A2; Lyso-PL, lyso-phospholipase. Straight
lines represent the phospholipid synthetic pathways while dotted lines represent the degradation pathways. b Representative 31P-MR spectra
of the aqueous fraction of cell extracts in the NHA model. Pi, inorganic phosphate; ATP, adenosine triphosphate. PC (c) and PE (d) levels in the
NHA model. e Representative 13C-MR spectra showing the build-up of [1-13C]-PC, [2-13C]-PC, [1-13C]-PE, and [2-13C]-PE over 48 h in live NHAIDHmut
cells in an MR-compatible bioreactor. Representative non-linear kinetic fits of de novo synthesis of [1-13C]-PC (f) and [2-13C]-PE (g) in the NHA model
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quantified using Mnova (Mestrelab), corrected for satur-
ation effects, and normalized to cell number and to an
external reference (trimethylsilyl propionate for 1H- and
13C-MR and methylene diphosphonic acid for 31P).
MRS of live cells
13C-MRS studies to quantify flux from [1,2-13C]-choline
and [1,2-13C]-ethanolamine to PC and PE in live cells
were performed on a 600-MHz Bruker spectrometer
using a 10-mm broadband probe as previously described
[20]. Cells were grown on fibronectin-coated microcar-
rier beads (Pronectin-F, Pall Corporation) and assembled
into an MR-compatible bioreactor system [20, 21].
Briefly, a perfusion system consisting of one inflow and
two outflow lines was combined with a 10-mm NMR
tube at the bottom of which the microcarrier beads with
cells were placed. This allowed continuous circulation of
culture medium (DMEM) in which choline was replaced
with 56 μM [1,2-13C]-choline (Sigma-Aldrich) to meas-
ure PC synthesis, and 56 μM [1,2-13C]-ethanolamine
(Sigma-Aldrich) was added in order to measure PE
synthesis. The incorporation of [1,2-13C]-choline and
[1,2-13C]-ethanolamine into 13C-labeled PC and PE was
monitored over the course of 48 h. Prior to and at the
end of every study, proton-decoupled 31P-MR spectra
(30° flip angle, 3 s relaxation delay, and 1024 transients)
were obtained to confirm cell viability and to verify that
steady-state PC and PE levels matched those obtained
from cell extracts (within experimental error). Proton-
decoupled 13C-MR spectra were acquired in 2 h blocks
using a 30° flip angle, 6 s relaxation delay, and 2400
transients. Peak integrals were quantified using Mnova
(Mestrelab Research), corrected for saturation and NOE,
and normalized to cell number and to a metabolite of
known concentration (1.59 mM inorganic phosphate for
31P-MR spectra and 5 mM [1-13C]-glucose added to the
medium for this purpose for 13C-MR spectra). The
build-up of 13C-labeled PC and PE over time was ana-
lyzed using a non-linear kinetic model (GraphPad Prism)
that assumes that PC and PE are primarily generated by
choline/ethanolamine phosphorylation [20]. Therefore,
the kinetics of PC build-up are expected to follow the
equation 13CPC(t) = A (1−e−kt) where 13CPC represents
13C-labeled PC at time point t, A represents the asymp-
totic value of the 13C-labeled pool of PC, i.e., the total
steady state PC pool, and k is the pseudo-first-order rate
constant for CK. A similar equation was used to quantify
PE build-up and obtain a pseudo-first-order rate con-
stant for EK.
CK and EK activity
CK activity was determined using 31P-MR spectroscopy
as described earlier [22]. A similar assay was developed
for determining EK activity: cells or tumor tissue were
lysed in buffer (10 mM glycylglycine, pH 8, 2 mM di-
thiothreitol) and lysate added to reaction mix (60 mM
glycylglycine, pH 8, 3 mM ethanolamine, 4 mM ATP,
and 4 mM MgCl2). Proton-decoupled
31P-MR spectra
(30° flip angle, 2.6 s relaxation delay, 128 transients)
were then acquired every 5 min and PE concentration
quantified from peak integrals as described above. EK
activity was measured by linear regression of the time
course of PE production.
Western blotting
Cells (~ 107) were lysed by sonication in RIPA buffer
(25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% so-
dium deoxycholate, 0.1% SDS) containing 150 nM aprotinin
and 1 μM each of leupeptin and E64 protease inhibitor. For
HIF-1α analysis, nuclear extracts were prepared using the
NE-PER fractionation kit (Thermo-Fisher Scientific) accord-
ing to manufacturer’s instructions. Lysates were cleared by
centrifugation at 14,000 rpm for 15 min at 4 °C and boiled
in SDS-PAGE sample buffer (95 °C for 10 min). Total cellu-
lar protein (~ 20 μg) was separated on a 10% polyacrylamide
gel (Bio-Rad) by sodium dodecyl sulphate polyacrylamide
gel electrophoresis, transferred onto Immobilon-FL PVDF
membrane (Millipore) and probed for HIF-1α (Cell Signal-
ing, 3716), CKα (Abcam, ab38290), ETNK1 (Thermo-Fisher,
PA5-28325), and ETNK2 (Thermo-Fisher, PA5-38807). β-
Actin (Cell Signaling, 4970), GAPDH (Cell Signaling, 2118),
and β-tubulin (Cell Signaling, 2128) were used as loading
control.
Animal studies
Animal studies were conducted in accordance with the
University of California Institutional Animal Care and
Use Committee (IACUC) guidelines under protocol
number AN101013. U87IDHwt and U87IDHmut cells
(3 × 105cells/10 μl) were intracranially injected into athy-
mic nu/nu mice (Simonsen Laboratories) by the free-
hand technique. T2-weighted MR imaging used to moni-
tor tumor volume was performed on a 14.1-T vertical
MR system (Agilent Technologies) equipped with a
single-channel 1H coil. Images were acquired using a
multislice spin-echo sequence with the following param-
eters: time-to-echo 20 ms; repetition time 1200 ms; field
of view 25 × 25 mm2; matrix 512 × 256; slice thickness
1.0 mm; and number of averages 2. Tumor contours in
each axial slice were drawn manually, and tumor volume
was determined as a sum of the areas multiplied by slice
thickness using in-house MR software (SIVIC). When
the tumors reached ~ 100 mm3, the animals were sacri-
ficed and tumor tissue snap frozen for metabolic and
biochemical analysis (n = 5 for U87IDHwt, n = 7 for
U87IDHmut).
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DNA hypermethylation
Analysis of methylation of CHKA, ETNK1, and ETNK2
genes was performed as previously described [6]. Briefly,
genomic DNA was isolated; bisulfite was converted
using the EZ DNA MethylationKit (Zymo Research) and
processed on Infinium Human Methylation 450 bead
arrays (Illumina). Probes that were significantly different
between IDHwt and IDHmut cells were identified using
the Limma (moderated t test) approach as described
previously [23, 24]. The ratio between methylated probe
intensity and total probe intensity, which can be inter-
preted as the percentage of methylation, was designated
as the beta (β) value and used to calculate the Δβ values
(the difference between IDHmut and IDHwt cells) for
each gene.
Patient samples
Flash-frozen human tumor tissue (n = 4 IDHwt, n = 3
IDHmut), with no patient-identifying information, was
obtained in compliance with informed consent policy
from the UCSF Brain Tumor Center Biorepository and
Pathology Core. The Committee on Human Research at
UCSF approved sample use, and the Institutional Review
Board at UCSF approved research. Tumors were consid-
ered IDHmut if they were immunopositive with the anti-
IDH1 R132H antibody (DIA-H09, Dianova) and IDHwt if
negative for IDH1 mutation, EGFR amplification, and/or
PTEN loss as determined clinically by FISH.
TCGA data analysis
Mean normalized z-scores for CHKA, ETNK1, and
ETNK2 mRNA expression (RNA Seq V2 RSEM dataset)
and DNA methylation (HM450 dataset) were calculated
from data for low-grade glioma (grades II and III)
patient biopsies deposited in the larger TCGA database
(http://cancergenome.nih.gov) and downloaded via the
CBio Portal (http://www.cbioportal.org) [25, 26].
Statistical analysis
All experiments were performed on a minimum of five
samples and results presented as mean ± standard devi-
ation. Statistical significance was assessed using an un-
paired two-tailed Student’s t test assuming unequal
variance with p < 0.05 considered significant. “*” repre-
sents p < 0.05, “**” represents p < 0.01, and “***” repre-
sents p < 0.005. NS indicates that there is no statistically
significant difference.
Results
PC and PE synthesis is downregulated in IDHmut glioma
cells
We examined PC and PE synthesis in two cell models, a
U87 glioblastoma-based model and an immortalized nor-
mal human astrocyte (NHA) model. In each case, the cells
were genetically engineered to express either IDHwt or
IDH1 R132H mutant enzyme [11]. Using 1H-MRS, we
previously reported that steady-state PC levels were re-
duced in IDHmut cells relative to IDHwt [11]. Separately,
Esmaeili et al. used 31P-MRS to show that steady-state PE
was reduced in IDHmut gliomas relative to IDHwt [13].
Here, we used 31P-MR analysis of cell extracts (Fig. 1b) to
confirm both of these findings in our models. Steady-state
PC as well as PE were significantly reduced in IDHmut
cells relative to IDHwt in both NHA (Fig. 1c, d) and U87
(Additional file 1: Figure S1A-B) models. We also
confirmed that steady-state PC pool sizes as deter-
mined by 31P-MRS matched the values previously de-
termined by 1H-MRS in both our NHA and U87
models (Additional file 1: Figure S1C-D).
We then used 13C-MRS to monitor PC and PE synthesis
in live cells perfused with [1,2-13C]-choline and [1,2-13C]-
ethanolamine over 48 h (Fig. 1e). This time course was
chosen because steady-state pools of PC and PE were filled
by 48 h (as determined by comparing to our 31P-MRS data,
Additional file 1: Figure S1E-H) while breakdown products
of PtdCho and PtdE such as 13C-GPC and 13C-GPE were
below detection, indicating that 13C-labeled PC and PE was
generated primarily de novo from extracellular 13C-choline
and 13C-ethanolamine. The kinetic fits for PC and PE
build-up are shown in Fig. 1f, g for the NHA model and in
Additional file 1: Figure S1I-J for the U87 model. The
pseudo-first-order rate constant for CK dropped signifi-
cantly by 40% from 0.08 ± 0.007 h−1 in NHAIDHwt to 0.05
± 0.004 h−1 in NHAIDHmut and by 39% from 0.1 ± 0.008 h
−1 in U87IDHwt to 0.06 ± 0.007 h−1 in U87IDHmut. Simi-
larly, the pseudo-first-order rate constant for EK decreased
significantly by 50% from 0.06 ± 0.005 h−1 to 0.03 ± 0.004 h
−1 in the NHA model and by 40% from 0.08 ± 0.005 h−1 to
0.05 ± 0.003 h−1 in the U87 model.
CK activity and EK activity are reduced in IDHmut glioma
cells
Next, we examined the expression and activity of CK
and EK, the enzymes responsible for PC and PE synthe-
sis (Fig. 1a) in our models. In mammalian cells, CK
exists in three isoforms, CKα1 and CKα2 (encoded by
the CHKA gene) and CKβ (CHKB gene), of which the α
but not β isoforms have been associated with malignant
transformation [9, 10]. In our IDHmut cells, CKα
expression was significantly reduced relative to IDHwt
(Fig. 2a, b). Using a 31P-MR-based assay (Fig. 2c), we
also measured CK activity in cell lysates and found a sig-
nificant reduction in IDHmut cells relative to IDHwt in
both NHA (61%, Fig. 2d) and U87 (60%, Fig. 2e) models.
EK is encoded by the ETNK1 and ETNK2 genes [27, 28].
We were unable to detect expression of ETNK1 or ETNK2
using commercially available antibodies in our models (data
not shown). Nonetheless, measurement of EK, or EK-like
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activity in cell lysates (Fig. 2f), showed a significant reduc-
tion in IDHmut cells relative to IDHwt in both NHA (65%,
Fig. 2g) and U87 (54%, Fig. 2h) models.
2-HG mediates the reduction in CK activity and EK activity
as well as PC and PE levels
In an effort to link our results to the IDH1 mutation, we
pharmacologically manipulated the presence of 2-HG
and examined choline and ethanolamine metabolism in
IDHwt cells incubated with 2-HG or in IDHmut cells
treated with the IDHmut enzyme inhibitor AGI-5198
[29, 30]. PC and PE levels were reduced in IDHwt cells
treated with 2-HG in both NHA (Fig. 3a, b) and U87
(Additional file 1: Figure S2A-B) models. Conversely,
inhibiting 2-HG production by treating IDHmut cells
with AGI-5198 restored PC and PE to levels similar to
those observed in IDHwt cells. Concomitantly, CKα ex-
pression, CK activity, and EK activity were reduced in a
manner linked to the presence of 2-HG in both NHA
(Fig. 3c–e) and U87 (Additional file 1: Figure S2C-E)
models. Collectively, these results mechanistically linked
2-HG to the downregulation of PC and PE synthesis in
IDHmut glioma cells.
HIF-1α downregulates CK and EK activity
Next, we looked for the molecular mechanism by which
2-HG downregulates PC and PE synthesis in IDHmut
gliomas. HIF-1α has previously been reported to modu-
late CKα expression and PC levels in cancer [31, 32].
Furthermore, we and others previously demonstrated
that HIF-1α levels are post-translationally stabilized in






Fig. 2 CK activity and EK activity are downregulated in IDHmut glioma cells. CKα expression in the NHA (a) and U87 (b) models. c Representative
31P-MR assay for CK activity showing PC build-up following addition of cell lysate to a reaction mix containing choline and ATP. The inset shows
the rate of PC production in the NHA model. Quantification of CK activity in the NHA (d) and U87 (e) models. f Representative 31P-MR assay for
EK activity showing PE build-up following addition of cell lysate to a reaction mix containing ethanolamine and ATP. The inset shows the rate of
PE production in the NHA model. Quantification of EK activity in the NHA (g) and U87 (h) models
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of the activity of the prolyl hydroxylases that target
HIF-1α for degradation [30, 33–36]. Here, by examining
HIF-1α levels in IDHwt cells treated with 2-HG and in
IDHmut cells treated with AGI-5198, we confirmed that
higher HIF-1α levels are linked to the presence of 2-HG in
both NHA (Fig. 4a) and U87 (Additional file 1: Figure S3A)
models. We then questioned whether HIF-1α was linked to
PC and PE synthesis in our models. To this end, we si-
lenced HIF-1α expression by RNA interference in both
IDHwt and IDHmut cells (Fig. 4b and Additional file 1:
Figure S3B). Silencing HIF-1α did not alter PC, PE, CKα
expression, CK activity, or EK activity in IDHwt cells in both
NHA (Fig. 4c–g) and U87 (Additional file 1: Figure S3C-G)
models. In contrast, HIF-1α silencing restored PC, PE, CKα
expression, CK activity, and EK activity to levels similar to
those observed in IDHwt cells in both NHA (Fig. 4c–g) and
U87 (Additional file 1: Figure S3C-G) models. We also
established that treating IDHmut cells with 2-HG did not
rescue the effects of HIF-1α silencing on PC (Add-
itional file 1: Figure S4A-B), PE (Additional file 1: Figure
S4C-D), CK activity (Additional file 1: Figure S4E-F), or EK
activity (Additional file 1: Figure S4G-H). These results are
in line with the observation that 2-HG stabilizes HIF-1α
post-translationally [30, 33–36], while siRNA-mediated HIF-
1α silencing occurs at the post-transcriptional level [37].
Taken together, these results suggest that 2-HG-mediated
stabilization of HIF-1α downregulates CK activity and EK
activity and thus leads to reduced PC and PE levels in IDH-
mut glioma cells.
Finally, 2-HG can alter gene expression in glioma cells
via DNA hypermethylation [38, 39]. We, therefore, ex-
amined the methylome of IDHwt and IDHmut cells to
determine whether the CHKA, ETNK1, or ETNK2 genes
were hypermethylated in our models. There was no
significant difference in the Δβ value (difference in %
methylation between IDHmut and IDHwt cells) of these
genes in our NHA (Δβ = 0.02, p = 0.4, probe cg27431247
for CHKA, Δβ = 0.01, p = 0.5, probe cg25881344 for
ETNK1, and Δβ = 0.03, p = 0.2, probe cg08114257 for
ETNK2) or U87 (Δβ = 0.04, p = 0.1, probe cg27431247
for CHKA, Δβ = 0.03, p = 0.3, probe cg25881344 for
ETNK1, and Δβ = 0.01, p = 0.2, probe cg08114257 for
ETNK2) models. These results potentially rule out epi-
genetic effects of 2-HG on CK and EK expression in our
models and suggest that the effect of 2-HG on PC and
PE levels is primarily mediated by HIF-1α.
2-HG downregulates PC and PE synthesis in the BT54
patient-derived IDHmut glioma model
In order to confirm our findings in a clinically relevant
IDHmut glioma model, we examined the BT54 patient-
derived neurosphere model [19], which retains both
IDHwt and IDHmut alleles and produces 2-HG [5, 19].





Fig. 3 2-HG is responsible for the downregulation of PC and PE synthesis in IDHmut glioma cells. PC (a), PE (b), CKα expression (c), CK activity (d),
and EK activity (e) in NHAIDHwt cells, NHAIDHwt cells incubated with 2-HG, NHAIDHmut cells, and NHAIDHmut cells treated with AGI-5198
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models, treating BT54 neurospheres with AGI-5198
increased PC, PE, CKα expression, CK activity, and EK
activity (Fig. 5a–e), an effect that was associated with
reduced HIF-1α levels (Fig. 5f ). Importantly, silencing
HIF-1α (Fig. 5g) increased PC, PE, CKα expression, CK
activity, and EK activity (Fig. 5h–l), confirming the link
between HIF-1α and downregulation of PC and PE
synthesis in the clinically relevant BT54 model.
PC and PE levels are reduced in IDHmut gliomas in
orthotopic tumor xenografts
Next, we examined PC and PE synthesis in U87IDHwt
and U87IDHmut orthotopic tumor xenografts. We
assessed extracts from tumors that had reached compar-
able sizes as determined by T2-weighted MR imaging
(Fig. 6a). As shown in Fig. 6b, c, PC and PE levels were
reduced in U87IDHmut tumors relative to U87IDHwt. Con-
comitantly, CKα expression (Fig. 6d and Additional file 1:
Figure S5A), CK activity (Fig. 6e), and EK activity (Fig. 6f)
were reduced in U87IDHmut tumors relative to U87IDHwt.
As in the case of our cell models, these metabolic
changes were accompanied by higher levels of HIF-1α
in U87IDHmut tumors relative to U87IDHwt (Fig. 6g
and Additional file 1: Figure S5B).
PC, PE, CKα expression, CK activity, and EK activity are
reduced in IDHmut glioma patient biopsies
In order to determine whether our findings were rele-
vant to human patients, we examined IDHwt and IDH-
mut glioma patient biopsies. Consistent with our results
in cell and animal models, levels of PC and PE were
reduced in IDHmut glioma patient biopsies relative to
IDHwt (Fig. 7a, b). Concomitantly, CKα expression, CK
activity, and EK activity were reduced in IDHmut patient
biopsies relative to IDHwt (Fig. 7c–e) and this effect was
accompanied by an increase in HIF-1α levels in IDHmut
biopsies (Fig. 7f ).
Finally, we also examined mRNA expression data for
the CKα (CHKA) and EK genes (ETNK1 and ETNK2) in
low-grade (grade II and grade III) patient biopsy samples
from The Cancer Genome Atlas (TCGA) database. As
shown in Additional file 1: Figure S6A-B, the mean z-
scores for CHKA and ETNK2 mRNA expression showed a





Fig. 4 HIF-1α downregulates PC and PE synthesis in IDHmut glioma cells. a Representative western blot showing the effect of 2-HG on HIF-1α in
the NHA model. b Representative western blots showing silencing of HIF-1α in the NHA model. Effect of HIF-1α silencing on PC (c), PE (d), CKα
expression (e), CK activity (f), and EK activity (g) in the NHA model
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to IDHwt (0.21 in IDHwt to − 0.16 in IDHmut, p < 0.0001
for CHKA and 0.69 in IDHwt to − 0.12 in IDHmut, p <
0.001 for ETNK2). There was no significant difference in
ETNK1 mRNA expression (Additional file 1: Figure S6C,
0.11 in IDHwt vs. 0.29 in IDHmut, p = 0.2). We also ex-
amined DNA methylation for CHKA, ETNK1, and ETNK2
genes within the IDHmut glioma population and, in line
with the results in our cell models, found no correlation
with mRNA z-scores (Pearson correlation coefficients of
− 0.2 for CHKA, − 0.3 for ETNK1, and − 0.3 for ETNK2;
Additional file 1: Figure S6d-f), suggesting that reduced
CHKA and ETNK2 mRNA expression in the IDHmut gli-
oma patient samples was not the result of 2-HG-induced
DNA hypermethylation at the promoters of these genes.
Discussion
In this study, we show that IDHmut gliomas downregu-
late PC and PE synthesis relative to IDHwt gliomas. This
effect is mediated by 2-HG via HIF-1α stabilization and
the subsequent downregulation of CK and EK or EK-like
activity. Our finding that PC is reduced confirms our
previous publication [11], and our results are also in line
with the study by Reitman et al. who also showed re-
duced PC levels in IDHmut glioma cells relative to
IDHwt [12]. Esmaeili et al. reported unchanged PC levels
in IDHmut gliomas relative to IDHwt [13], but the same
study showed a reduction in PE in IDHmut gliomas,
consistent with our observations.
PC and PE are precursors in the synthesis of the phospho-
lipids PtdCho and PtdE, which are structural components of
cellular membranes [7]. Due to the higher demand for phos-
pholipids associated with cell proliferation, tumor cells often
upregulate phospholid biosynthesis [8, 28, 40]. In contrast,
we recently demonstrated that 2-HG downregulates PtdCho
and PtdE biosynthesis in IDHmut gliomas by inducing
autophagic degradation of the endoplasmic reticulum (ER-
phagy) [41]. Our observation that PC and PE levels are re-
duced in IDHmut gliomas is consistent with the reduction
in PtdCho and PtdE levels. However, further studies are
needed to assess whether the reduction in PC and PE levels
induced by HIF-1α is mechanistically linked to the reduction
in PtdCho and PtdE levels in IDHmut gliomas and, con-
versely, whether ER-phagy contributes to the reduction in







Fig. 5 2-HG, acting via HIF-1α, downregulates PC and PE synthesis in the BT54 patient-derived IDHmut glioma model. Effect of AGI-5198 on PC
(a), PE (b), CKα expression (c), CK activity (d), EK activity (e), and HIF-1α (f) in the BT54 model. g Representative western blots showing silencing of
HIF-1α in the BT54 model. Effect of HIF-1α silencing on PC (h), PE (i), CKα expression (j), CK activity (k), and EK activity (l) in the BT54 model




Fig. 6 PC and PE synthesis is downregulated in orthotopic IDHmut glioma xenografts. a Representative axial T2-weighted MR images of U87IDHwt
and U87IDHmut orthotopic tumor-bearing mice. Tumor regions have been manually contoured in white. PC (b), PE (c), CKα expression (d), CK activity




Fig. 7 PC and PE synthesis is downregulated in IDHmut glioma patient biopsies. PC (a), PE (b), CKα expression (c), CK activity (d), EK activity (e),
and HIF-1α (f) in IDHwt and IDHmut glioma patient biopsies
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We find that reduced CK activity is associated with re-
duced CKα expression in cell models, tumor xenografts,
and patient biopsies. Importantly, CKα (CHKA) mRNA
expression is reduced in IDHmut patient biopsies rela-
tive to IDHwt in the TCGA low-grade glioma dataset.
These results are consistent with the central role of CKα
in modulating PC levels in cancer [8–10]. CK catalyzes
the first committed step in phosphatidylcholine biosyn-
thesis which is the phosphorylation of free choline to PC
[10, 42], and studies have shown that this reaction can
be rate limiting in cancer cells [42, 43]. With regard to
PE, the ethanolamine-specific EK enzymes encoded by
the ETNK1 and ETNK2 genes mediate PE synthesis in
mammalian cells [27, 28]. Although we were unable to
detect expression of ETNK1 or ETNK2 in any of our
samples using commercially available antibodies, it is
important to note that ETNK2 mRNA levels are re-
duced in IDHmut patient biopsies relative to IDHwt
in the TCGA dataset. Further studies are needed to
confirm the molecular determinant of PE synthesis in
IDHmut gliomas, but it is important to note that CK,
which also possesses EK activity, could serve to phos-
phorylate ethanolamine to PE [9, 10, 44] in IDHmut
gliomas.
Our study points to HIF-1α as the primary driver
behind reduced CK and EK activity and thus PC and PE
levels in IDHmut gliomas. Consistent with our observa-
tions, we found no evidence of methylation of the
CHKA, ETNK1, and ETNK2 genes in our models or in
IDHmut glioma patient biopsies in the TCGA dataset,
suggesting that 2-HG-induced DNA hypermethylation
may not play a major role in downregulating CK and EK
activity in IDHmut glioma cells. HIF-1α is a subunit of
the HIF transcription factor that regulates expression of
several genes involved in tumor proliferation, metabol-
ism, and adaptation to hypoxic stress [45, 46]. In the
context of phospholipid metabolism, HIF-1α has been
linked to activation as well as repression of CK expres-
sion and activity [31, 32]. Furthermore, HIF-1α function
can be regulated in a cell type- and context-dependent
manner [47]. It is therefore possible that, in IDHmut
gliomas, HIF-1α downregulates CK activity. With regard
to EK, our study is the first to report downregulation of
EK activity by HIF-1α. Further studies are needed to de-
lineate the mechanism by which HIF-1α downregulates
CK and EK activity in IDHmut gliomas.
Cellular HIF-1α levels are tightly regulated by post-
translational degradation. Under normoxic conditions,
HIF-1α is targeted for proteasomal degradation as a result
of prolyl hydroxylation that is mediated by α-KG-
dependent prolyl hydroxylases [45, 46]. Our finding that
2-HG stabilizes HIF-1α in IDHmut cells, even under
normoxic conditions, is consistent with our previous pub-
lication [30] as well as previous reports by others
indicating that 2-HG competitively inhibits prolyl hydrox-
ylase activity, resulting in HIF-1α stabilization [33–36].
However, other studies have reported unchanged or lower
HIF-1α levels in IDHmut gliomas relative to IDHwt [48,
49]. It should be noted that multiple α-KG-dependent
prolyl hydroxylases are involved in HIF-1α hydroxylation
[50] and the intracellular expression of these enzymes, as
well as the efficacy with which 2-HG inhibits these
enzymes, together with local levels of hypoxia, may vary,
potentially accounting for the discrepancies in HIF-1α
expression across different studies.
The complexity of factors affecting HIF-1α levels iden-
tifies a potential challenge in using PC and/or PE as
imaging biomarkers of IDH status. Another potential
confounder that could limit the utility of PC and PE is
variability in 2-HG levels. Our results indicate that in
IDHmut gliomas PC and PE are directly linked to the
ongoing presence of 2-HG. However, a recent study has
shown that a small proportion (~ 12%) of IDHmut gli-
omas spontaneously lose the IDHwt or IDHmut allele,
thereby losing the ability to produce 2-HG, an effect that
was also associated with progression to a higher grade
tumor [51, 52]. Our results suggest that PC and PE syn-
thesis would increase in these tumors. In addition, some
ex vivo studies show a correlation between tumor cellu-
larity and PC levels. Accordingly, and consistent with
our findings, tissue samples from low-grade (WHO
grades II and III) IDHmut gliomas that have undergone
malignant progression to a higher cellularity, higher
grade (grade IV), glioblastoma show an increase in PC
levels and these levels are at least as high as those
observed in primary IDHwt glioblastomas [53–55].
In the clinical setting, some in vivo 1H-MRS studies
suggest that tCho, normalized to creatine or to N-acety-
laspartate, is higher in higher grade gliomas relative to
low-grade [17, 56] and that these ratios could distinguish
low-grade IDHmut gliomas from high-grade IDHwt
glioblastomas [57, 58]. Most importantly, however, inde-
pendent of IDH status, when compared to normal brain,
normalized tCho is always elevated in the tumor region
[59], and thus elevated tCho remains an important and
useful indicator of tumor for patients with all brain tumor
types [54, 59].
Conclusions
Our study establishes a role for 2-HG, acting via HIF-1α,
in the downregulation of PC and PE synthesis in IDHmut
gliomas. These results point to potential challenges in
using PC and/or PE as indicators of tumoral IDH status.
More importantly, our findings underscore the unusual
metabolic reprogramming of IDHmut gliomas [3]. As
mentioned, previous studies have identified other meta-
bolic pathways that are reprogrammed differently in
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IDHmut gliomas compared to IDHwt gliomas [3, 5, 6].
Here, we show, to our knowledge for the first time,
oncometabolite-driven downregulation of choline and eth-
anolamine metabolism in cancer. Our findings thus ex-
pand our understanding of the unique metabolic
reprogramming associated with the IDH1 mutation.
Additional file
Additional file 1: Figures S1-S6. Provided as a single file containing
figures and associated legends. (PDF 895 kb)
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